Ascendis Pharma A/S (NASDAQ:ASND – Free Report) – Stock analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for Ascendis Pharma A/S in a report released on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will earn ($6.44) per share for the year, up from their previous estimate of ($6.50). The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.12) per share. Leerink Partnrs also issued estimates for Ascendis Pharma A/S’s Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($1.90) EPS, Q2 2025 earnings at ($1.81) EPS, Q3 2025 earnings at ($1.74) EPS, Q4 2025 earnings at ($1.66) EPS, FY2025 earnings at ($7.12) EPS and FY2026 earnings at ($2.00) EPS.
ASND has been the subject of several other research reports. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. JPMorgan Chase & Co. cut their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. Stifel Nicolaus increased their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Wedbush reaffirmed an “outperform” rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Finally, TD Cowen decreased their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $192.07.
Ascendis Pharma A/S Price Performance
NASDAQ:ASND opened at $125.82 on Wednesday. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $161.00. The business has a 50 day simple moving average of $133.19 and a 200 day simple moving average of $133.34. The firm has a market capitalization of $7.64 billion, a P/E ratio of -15.57 and a beta of 0.65.
Hedge Funds Weigh In On Ascendis Pharma A/S
Institutional investors have recently bought and sold shares of the business. Signaturefd LLC lifted its position in Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after buying an additional 80 shares in the last quarter. Profund Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 3.0% during the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock worth $398,000 after purchasing an additional 85 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 143 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ascendis Pharma A/S in the third quarter valued at approximately $30,000. Finally, GAMMA Investing LLC increased its holdings in shares of Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 214 shares in the last quarter.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Recommended Stories
- Five stocks we like better than Ascendis Pharma A/S
- How is Compound Interest Calculated?
- Oracle Announces Game-Changing News for the AI Industry
- Best Aerospace Stocks Investing
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- What is the Shanghai Stock Exchange Composite Index?
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.